A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Trial details
- Registry ID
- NCT06586112
- Phase
- Phase 3
The FDA approved Apremilast on 21 Mar 2014.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisNCT06586112 | ALMS | Phase 3 | Completed | 2025-09-19Actual |
| A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001NCT06588738 | ALMS | Phase 3 | Completed | 2025-09-23Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-03-21Day | Apremilast | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA205437", "applicant_as_listed_by_fda": "AMGEN INC", "brand_names": ["OTEZLA"], "active_ingredients": ["APREMILAST"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140321", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |